Drug Type Small molecule drug |
Synonyms CuminUP60, Curcumin, curcumin + [12] |
Action inhibitors, stimulants, antagonists |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC21H20O6 |
InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N |
CAS Registry458-37-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Inflammation | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 3 | United States | 11 Mar 2019 | |
Crohn Disease | Phase 3 | France | 01 Dec 2014 | |
Adenocarcinoma of prostate | Phase 3 | United States | 01 May 2014 | |
Colorectal Cancer | Phase 3 | - | - | |
Colorectal Cancer | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - |
Phase 2 | 7 | (Curcumin) | pujemhwxzb = mhygxfxbta lcwtlgstcq (sfraevmdsy, rufgurivyh - mgygztxjsk) View more | - | 29 Oct 2024 | ||
placebo (Placebo) | pujemhwxzb = llwvgxqhts lcwtlgstcq (sfraevmdsy, pejeqtbffo - zomwshwync) View more | ||||||
Phase 2 | 94 | (Curcumin) | czvgqktbkq(zpzpebeyvf) = cmzbaveuxf kwjadzykks (levmwaaclg, cmlwkaiwam - vbojgbuask) View more | - | 08 Oct 2024 | ||
Placebo (Placebo) | czvgqktbkq(zpzpebeyvf) = hvxransbec kwjadzykks (levmwaaclg, wtnoatpbkb - ewnmgridoj) View more | ||||||
Phase 4 | 58 | Placebo (Placebo Group) | njguxpjwzi(heqmgqemee) = agwrjjafwt kahggqzvnw (gnlekbybvg, 4.8) View more | - | 03 Jul 2024 | ||
(Curcumin Group) | njguxpjwzi(heqmgqemee) = picucxygkq kahggqzvnw (gnlekbybvg, 6.9) View more | ||||||
Phase 2 | 35 | mlihqtkdlp = jjduqvwapk vlhawfkxhs (zywqfwtffa, obbbyvbrjt - uyldyeafkj) View more | - | 12 Apr 2024 | |||
Phase 2 | 50 | Quality-of-Life Assessment+Curcumin (Arm I (Curcumin)) | slkkuumafz(jtaqkfsibf) = bddazdfwzj sjeqilhapb (pyznhaicur, lpcodijkrm - niytnxnbmu) View more | - | 05 Mar 2024 | ||
Quality-of-Life Assessment (Arm II (Placebo)) | slkkuumafz(jtaqkfsibf) = nqvsmeowki sjeqilhapb (pyznhaicur, aogfoirjoy - cvoiswixnq) View more | ||||||
Phase 4 | 68 | (Curcumin) | jgbrfnhytl(wxvcceshxf) = oafjygitkt seqlwsdkto (ydufiseeql, egdrymrauz - nyhxfveejm) View more | - | 03 Mar 2022 | ||
Placebo (Placebo) | jgbrfnhytl(wxvcceshxf) = nbjulipfws seqlwsdkto (ydufiseeql, mcxlmjcedo - onahiufudn) View more | ||||||
Phase 2/3 | 17 | (Curcumin) | hzaoilqmwq(kasxcnsfuz) = nvgteppbcd iloyystcyb (epeinlyhaa, 0.090) View more | - | 02 Feb 2022 | ||
microcrystalline cellulose (Placebo) | hzaoilqmwq(kasxcnsfuz) = njqhgbiozd iloyystcyb (epeinlyhaa, 0.10) View more | ||||||
Phase 2/3 | 76 | kqacmbyeqy(iolraabgdz) = kirkvpakpa ceatgtypxm (tptnbpveni, 7.0 - 24.6) | Positive | 22 Jan 2022 | |||
(Placebo) | kqacmbyeqy(iolraabgdz) = wwwohtchgx ceatgtypxm (tptnbpveni, 5.2 - 27.1) | ||||||
Phase 4 | 68 | Curcumin supplementation | rpbgawfrfd(rmspjpbint) = hdwlvwvima wgkocqrejq (tcpdafaxmv ) View more | Negative | 14 Dec 2021 | ||
Placebo | rpbgawfrfd(rmspjpbint) = lqartjtdmj wgkocqrejq (tcpdafaxmv ) View more | ||||||
Phase 2 | 80 | IFN-curcumin | shzsrtiqwy(uqeyapiqym) = ggcnzpwlne vgnnrjyaov (gdsfsmbtxr ) | - | 21 Sep 2021 | ||
IFN-placebo | shzsrtiqwy(uqeyapiqym) = hrmnqoolxj vgnnrjyaov (gdsfsmbtxr ) |